Chest ACCP Career Connection
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (13)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Alothman, G. A.
Right arrow Articles by Coates, A. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Alothman, G. A.
Right arrow Articles by Coates, A. L.
(Chest. 2005;127:522-529.)
© 2005 American College of Chest Physicians

Bronchial Constriction and Inhaled Colistin in Cystic Fibrosis*

Ghassan A. Alothman, MD; Bernard Ho, BSc; Muslim M. Alsaadi, MD, ABP; Sharon L. Ho, BSc, RRT; Lisa O’Drowsky, BSc, RRT; Emily Louca, BSc, RRT and Allan L. Coates, BEng (Elect), MDCM

* From the Division of Respiratory Medicine, Hospital for Sick Children, University of Toronto, Toronto, ON, Canada.

Correspondence to: Allan L. Coates, BEng, MDCM, Division of Respiratory Medicine, Hospital for Sick Children, 555 University Ave, Toronto, ON, Canada M5G IX8; e-mail: allan.coates{at}sickkids.ca

Study objective: Inhaled colistin is used for the treatment of Pseudomonas aeruginosa infection in cystic fibrosis (CF) patients despite reports of chest tightness and bronchospasm. The main objective of the study was to assess whether bronchospasm occurred in pediatric CF patients with or without clinical evidence of airway hyperreactivity.

Design and methods: A prospective placebo-controlled clinical trial with crossover design was devised using challenge tests with 75 mg colistin in 4 mL saline solution and a placebo solution of the same osmolarity using a breath-enhanced nebulizer for administration. Subjects were recruited as follows: high risk (HR) for bronchospasm due to a personal history of recurrent wheezing, a family history of asthma and/or atopy, or bronchial lability, as demonstrated in pulmonary function tests; or low risk (LR) without these characteristics.

Results: The mean FEV1 (expressed as the mean [± SD] fall from baseline) of the HR group (n = 12) fell 12 ± 9% after placebo was administered, and fell 17 ± 10% after colistin was administered. For the LR group (n = 8), the mean FEV1 fell 9 ± 4% following placebo administration and 13 ± 8% following colistin administration. There was a greater number of subjects in the HR group compared to the LR group, which had a mean fall in FEV1 of ≥ 15% (p < 0.01) after inhaling colistin. The differences between placebo and colistin therapy in the LR group were not significant.

Conclusion: The results demonstrated that colistin can cause bronchospasm, particularly in those patients with coexisting CF and asthma.

Key Words: bronchial spasm • colistin • cystic fibrosis • inhaled antibiotics




This article has been cited by other articles:


Home page
 Am J Health Syst PharmHome page
M. B. Shirk, K. R. Donahue, and J. Shirvani
Unlabeled uses of nebulized medications.
Am. J. Health Syst. Pharm., September 15, 2006; 63(18): 1704 - 1716.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American College of Chest Physicians.